Exercise and Psoriasis: A Conversation with Dr. Helen Young
Patients with psoriasis are at increased risk for cardiovascular disease —and lack of physical activity may be a driving cause.
Wednesday, October 19, 2022
Psoriasis News
THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results
Commentary: Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Placebo-controlled Phase 3 POETYK PSO-1 Trial
The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.
Friday, October 14, 2022
New App Available to Measure Quality of Life for People with Skin Conditions
Researchers at Cardiff University have created and launched The Official DLQI App, designed to measure the quality of life for people with skin conditions. The app is free to download in the Apple and Android stores and is now available in seven languages!
Tuesday, October 11, 2022
BIOMAP Collaboration Update: A Systemic Review on Biomarkers
Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.
Tuesday, September 27, 2022
U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)
Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years.
Wednesday, September 14, 2022
Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis
Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.
Wednesday, August 31, 2022
Arcutis Announces a Patient Assistance Program (PAP)
Arcutis Biotherapeutics, Inc announced Arcutis Cares, a patient assistance program (PAP) for financially qualified uninsured and underinsured patients.
Friday, August 26, 2022
Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) Meeting
The 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) was held Wednesday, July 6 – Friday, July 8, 2022, in Paris, France. The following congress report includes twelve summaries of presentations focusing on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
Friday, August 26, 2022
Happify Health and Almirall Partner Together to Launch Claro
Claro, a digital platform built to improve mental health for those with psoriasis who are living in Spain, the United Kingdom, and Italy.
Friday, August 12, 2022
Focus on Psoriasis: A Report from the 2022 Society for Investigative Dermatology (SID) Annual Meeting
The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.
Friday, August 12, 2022
Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)
Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients experience significantly less pain at the injection site.
Wednesday, August 10, 2022
Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older
ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.
Tuesday, August 9, 2022
Subscribe to the IPC Newsletter
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
The Next Era of Opportunity in Psoriasis: Spatial Transcriptomics